全身动脉血压决定失代偿期肝硬化中非选择性β受体阻滞剂的治疗窗
本研究在624例失代偿期肝硬化伴腹水患者中分析非选择性β受体阻滞剂对28天无移植生存的影响。平均动脉压可能比腹水、慢加急性肝衰竭或自发性细菌性腹膜炎更好地界定治疗窗。
核心结论
- 腹水、慢加急性肝衰竭和自发性细菌性腹膜炎不限制非选择性β受体阻滞剂在肝硬化患者中的安全使用。
- 平均动脉压可能是确定非选择性β受体阻滞剂治疗窗的更好指标。
研究设计与样本
- 研究分析了624例连续入组的失代偿期肝硬化伴腹水患者队列中非选择性β受体阻滞剂对28天无移植生存的影响。
- 研究探究了三个潜在限值:自发性细菌性腹膜炎、慢加急性肝衰竭、平均动脉压≤82和<65 mmHg。
主要发现
- 自发性细菌性腹膜炎且平均动脉压<65 mmHg者中,非选择性β受体阻滞剂治疗与肾损伤相关。
临床怎么用
- 在失代偿期肝硬化伴腹水患者中,平均动脉压可能有助于界定非选择性β受体阻滞剂的治疗窗。
- 平均动脉压<65 mmHg时非选择性β受体阻滞剂的生存获益完全丧失,合并自发性细菌性腹膜炎者用药与肾损伤相关。
- 平均动脉压≥65 mmHg时非选择性β受体阻滞剂与更优的无移植生存相关。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The safety of non-selective β-blockers in patients with advanced cirrhosis has been questioned in recent years. It was hypothesised that there is a particular therapeutic window. However, the specific limits still need to be determined. AIM: To evaluate potential limits of the therapeutic window of non-selective β-blocker therapy in patients with cirrhosis and ascites METHODS: The impact of non-selective β-blockers on 28-day transplant-free survival was analysed in a cohort of 624 consecutive patients with decompensated cirrhosis and ascites. Three potential limits were investigated: spontaneous bacterial peritonitis, acute-on-chronic liver failure, mean arterial blood pressure ≤ 82 and < 65 mm Hg. RESULTS: Treatment with non-selective β-blockers was associated with a higher 28-day transplant-free survival in the overall cohort (hazard ratio: 0.621; P = .035) as well as in patients with acute-on-chronic liver failure (hazard ratio: 0.578; P = .031) and those with spontaneous bacterial peritonitis (hazard ratio: 0.594; P = .073). In contrast, survival benefits were markedly attenuated in patients with a mean arterial blood pressure ≤ 82 mm Hg and completely lost in those with mean arterial blood pressure < 65 mm Hg (P = .536). In spontaneous bacterial peritonitis patients with a mean arterial blood pressure < 65 mm Hg non-selective β-blocker treatment was associated with renal impairment. Of note, among those with a mean arterial blood pressure ≥ 65 mm Hg non-selective β-blocker intake was consistently associated with superior transplant-free survival (hazard ratio: 0.582; P = .029) irrespective of the presence of spontaneous bacterial peritonitis (hazard ratio: 0.435; P = .028) or acute-on-chronic liver failure (hazard ratio: 0.480 P = .034). CONCLUSIONS: Ascites, acute-on-chronic liver failure and spontaneous bacterial peritonitis do not limit the safe use of non-selective β-blockers in patients with cirrhosis. Mean arterial blood pressure might represent a better indicator to determine the therapeutic window of non-selective β-blocker treatment.
引用
- Tergast TL, Kimmann M, Laser H, et al. Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis. Aliment Pharmacol Ther. 2019. PMID: 31373713. doi:10.1111/apt.15439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。